Bayer

How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division
How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division
BioPharma Dive
Bayer
AskBio
M&A
gene therapy
Flag link:
Can Merck and Bayer's newly approved Verquvo stand out in an ever-more-competitive heart failure field?
Can Merck and Bayer's newly approved Verquvo stand out in an ever-more-competitive heart failure field?
Fierce Pharma
Merck
Bayer
FDA
Verquvo
vericiguat
chronic heart failure
Flag link:
The top 10 largest biopharma M&A deals in 2020
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Flag link:
Bayer pharma chief admits to unfillable revenue gap despite potential blockbuster launches
Bayer pharma chief admits to unfillable revenue gap despite potential blockbuster launches
Fierce Pharma
Bayer
Eylea
Xalreto
Flag link:
JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran
JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran
Fierce Biotech
CureVac
Bayer
vaccines
COVID-19
JPMHC 2021
Flag link:
Biopharma Companies Entering 2021 With New Collabs, Partnerships
Biopharma Companies Entering 2021 With New Collabs, Partnerships
BioSpace
M&A
Argenx
Zai Lab
Dewpoint Therapeutics
Pfizer
CureVac
Bayer
Sanofi
Nurix Therapeutics
Flag link:
mRNA latecomer CureVac recruits Bayer to speed COVID-19 vaccine to market
mRNA latecomer CureVac recruits Bayer to speed COVID-19 vaccine to market
Fierce Pharma
MRNA
CureVac
Bayer
COVID-19
vaccines
Flag link:
Biotech Bayer's VC arm leads $105M round for 'gene circuit' startup Senti Bio
Biotech Bayer's VC arm leads $105M round for 'gene circuit' startup Senti Bio
Fierce Biotech
Bayer
venture capital
gene therapy
Senti Biosciences
Flag link:
Astrazeneca shows megamergers were still possible in 2020
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
Flag link:
Bayer Leaps into CAR T-Cell Therapy Scene with Atara Biotherapeutics Collaboration
Bayer Leaps into CAR T-Cell Therapy Scene with Atara Biotherapeutics Collaboration
BioSpace
Bayer
CAR-T
cell therapy
Atara
Flag link:
Bayer creates cell and gene therapy platform to support partners
Bayer creates cell and gene therapy platform to support partners
Fierce Biotech
Bayer
cell therapy
gene therapy
Asklepios BioPharmaceutical
Flag link:
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Fierce Biotech
Argenx
Bayer
FDA
priority reviews
efgartigimod
ITP
Flag link:
Bayer provides funding to five more digital health start-ups
Bayer provides funding to five more digital health start-ups
Pharmaforum
Bayer
digital health
funding
G4A
Flag link:
Bayer powers gene-editing startup Metagenomi to $65M A round
Bayer powers gene-editing startup Metagenomi to $65M A round
Fierce Biotech
Metagenomi
Bayer
CRISPR
gene therapy
gene editing
Flag link:
Bayer, ViiV and RB challenge limits of pharma marketing creativity with innovative thinking, executions and media
Bayer, ViiV and RB challenge limits of pharma marketing creativity with innovative thinking, executions and media
Fierce Pharma
Bayer
ViiV
Reckitt Benckiser
pharma marketing
GSK
digital marketing
DTC advertising
Flag link:
Bayer to buy AskBio for $2B in bid to become a gene therapy player
Bayer to buy AskBio for $2B in bid to become a gene therapy player
BioPharma Dive
Bayer
M&A
AskBio
gene therapy
Flag link:
Bayer faces an uphill fight with finerenone
Bayer faces an uphill fight with finerenone
EP Vantage
Bayer
diabetic kidney disease
kidney disease
clinical trials
finerenone
Invokana
Farxiga
Flag link:
Bayer drug shown to slow diabetic kidney disease
Bayer drug shown to slow diabetic kidney disease
NASDAQ
Bayer
clinical trials
diabeteic kidney disease
kidney disease
diabetes
finerenone
Flag link:
Blank check company merger creates cancer specialist Vincera
Blank check company merger creates cancer specialist Vincera
Pharmaforum
SPAC
Vincera
LifeSci Acquisition
oncology
cancer
Bayer
Flag link:
Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients
Bayer’s Adempas meets primary endpoint in phase 4 trial in PAH patients
Pharmaceutical Business Review
Adempas
Bayer
PAH
clinical trials
Flag link:

Pages